Acquisition-Driven Growth with Rising Margins and Uncontrolled Spending: The Mixed Signals from Richards Group
Richards Group Inc. (TSX: RIC) released its unaudited preliminary results for 2025 on March 6, 2026, providing insights valuable for any financial leader wanting to differentiate between real growth and "acquisition-driven" growth. The headline reads +5.5% in revenue reaching CAD 430.2 million. However, the fine print notes that this growth comes "primarily from acquisitions" and that, concurrently, organic revenues have declined in both Healthcare and Packaging.
What interests me more than the applause for growth is the mechanics behind it. 2025 reveals a combination often hinting at integration challenges: gross margin improves significantly, but adjusted EBITDA declines. In numbers: the gross margin rises to 41.9% (from 39.7%), while Adjusted EBITDAaL falls 3.7% to CAD 54.8 million, with its margin dropping to 12.7% (from 14.0%). When a company sells "better" but earns less per dollar sold, the bottleneck lies in the operational cost system, not in the product.
Moreover, the company introduced a new segmented report for its two core businesses, Healthcare and Packaging, replacing the traditional earnings call with a podcast to discuss preliminary results. The way they communicate doesn't change the essence: Richards Group's 2025 serves as a case study on how an acquisition strategy can enhance gross margins while simultaneously degrading operational profitability if the integration fails to convert fixed costs into productivity.
The Arithmetic of "Acquisition-Driven Growth": 5.5% Up, Organic Down
The central figure is clear: CAD 430.2 million in revenue for 2025, CAD 22.4 million more than in 2024. However, the breakdown is what defines the quality of the growth. Richards reports CAD 28.9 million in contribution from acquisitions, implying that the existing business, when aggregated, did not sustain the increase.
In Healthcare, organic revenue dropped CAD 6.3 million (-3.2%) to CAD 189.0 million. The company attributes part of the decline to non-recurrent capital equipment sales from the previous year and weaker demand in aesthetics. In Packaging, organic revenue fell CAD 4.4 million (-2.1%) to CAD 208.1 million, with a more visible hit in food & beverage, where a decline of CAD 5.2 million (-5.4%) was recorded. In the fourth quarter, the pattern repeats: revenues +5.8% to CAD 110.9 million, driven by CAD 14.9 million from acquisitions, while Packaging contracts 15.5%.
This trajectory presents a straightforward reading for SMEs looking to "buy size" or pondering it: growth through M&A functions as an accelerator but also as a temporary facade if organic growth is dwindling. This isn’t a moral judgment; it’s math. If organic revenue declines, the company becomes dependent on continued acquisitions to maintain the top line. That dependency can be strategic and valid, but it’s only sustainable if the acquirer rapidly captures synergies and turns that scale into more cash, not more complexity.
Richards, in fact, shows a positive point: it continues to generate cash and maintains low leverage. Its net debt stands at CAD 52.8 million with leverage of 0.96x over Adjusted EBITDAaL. This balance provides ammunition for further acquisitions. The operational question arising from these numbers is different: if organic growth does not recover, each new acquisition will have to compensate not only for market deceleration but also for the cost of operating a heavier platform.
Gross Margin Up, EBITDA Down: The Enemy Lies in Operating Expenses
Few signals are as revealing as this: gross margin up and EBITDA margin down. Richards reports CAD 180.2 million in gross profit for 2025 and a margin of 41.9%, a significant improvement from 2024. The company itself links this expansion to acquisitions in Healthcare with a better margin mix.
To this point, the narrative would be ideal: acquiring more profitable businesses increases margins and should elevate profitability. But adjusted EBITDA tells another story. The Adjusted EBITDAaL falls to CAD 54.8 million and the margin drops to 12.7%. The difference between the two narratives lies in the expenses that are growing faster than revenues.
The published figures are telling: Selling and distribution rise to CAD 82.1 million from 69.8. Administrative costs (before amortization) increase to CAD 31.2 million from 25.1. The company attributes this to the integration of acquisitions and a larger corporate team associated with converting from trust to corporation and scaling up. That’s plausible and common. What isn’t optional is the financial outcome: if operating expenses do not stabilize, the EBITDA margin will continue to be pressured even if the gross margin looks “nice.”
By segments, the story becomes even clearer. Healthcare delivers CAD 36.1 million in segmented adjusted EBITDA, +15.3%. Packaging, on the other hand, drops to CAD 22.6 million, -23.4%. In other words, acquisition expansion brought margin, but the Packaging segment lost strength and dragged the consolidated figure down.
For an SME, this asymmetry poses a practical warning: when one segment compensates for another, the temptation is to “manage” the problem with consolidation. The risk is financing a weak business with a strong one, normalizing the idea that the group is “doing well” while one segment undermines efficiency. In Richards’s case, the new segmented report helps prevent the consolidated picture from hiding that dynamic.
Cash, Working Capital, and the Hidden Cost of Integrating Acquisitions
A typical mistake is to look at EBITDA alone. Richards reports an Adjusted free cash flow of CAD 35.0 million in 2025, mainly used for dividends (CAD 15.1 million) and debt repayment (CAD 12.4 million). Up to this point, discipline: distributing and deleveraging. Additionally, they report separately disclosed items of CAD 7.8 million (acquisition costs, corporate conversion, patent dispute defense, loss from social engineering fraud, etc.). It’s inaccurate to extrapolate these items as a “new normal,” but it’s critical to acknowledge that integrating companies incurs real and sometimes unexpected bills.
The detail I care about in terms of financial architecture is working capital. Richards ended 2025 with CAD 90.1 million, an increase of CAD 24.4 million year-over-year. This increase includes acquired inventory, commitments for inventory purchases, and seasonal prepayments for trade shows in its healthcare OEM business.
This is pure integration: size increases, and with it, the need to finance inventory and longer operating cycles. In a well “client-funded” company, growth typically comes with healthy turnover and collections supporting expansion. When working capital inflates, the company can remain profitable, but it needs more cash to operate the same dollar of sales.
Richards has room due to its sub-1.0x leverage, but the pattern is the same I observe in SMEs acquiring distributors or portfolios: day one improves market coverage, day ninety brings the reality of inventory, systems integration, and the commercial cost to maintain accounts. If the organization cannot convert that working capital into higher turnover, growth will be financed by debt or dilution, not by customers.
Another structural detail is that Richards made three acquisitions for CAD 63.3 million in 2025, with CAD 5.0 million in contingent consideration. This adds pressure to execution: the company bought volume, and now returns depend on capturing operational efficiency and maintaining pricing, especially in an environment where Packaging, particularly in a rigid U.S. market and food and beverage sectors, faces macro pressures.
A Useful Lesson for SMEs: Growth Only Matters if It Covers Its Own Complexity
Richards's decision to segment Healthcare and Packaging is more than just an accounting change. It’s a recognition that with acquisitions, the consolidated picture can become a dangerous illusion. 2025 showcases that Healthcare is improving, Packaging is deteriorating, and the group overall remains in a middle ground: better gross margins, worse EBITDA margin.
The operational message is clear. The company can continue acquiring because it has the balance sheet to do so, but success now hinges on three measurable levers:
1) Expense Discipline: if selling, distribution, and administration grow faster than the margin mix, EBITDA will remain compressed.
2) Recovery of Organic Growth: when growth entirely derives from acquisitions, the company becomes a hostage to the M&A pipeline. This elevates integration risk and disperses commercial focus.
3) Working Capital Turnover: the CAD 24.4 million increase in working capital is the kind of silent consumption that doesn’t appear in the revenue headline. Beyond a certain size, the company competes not just on product and price but also on its cash cycle.
Richards also leaves a positive reminder: it is possible to acquire without destroying the balance sheet. With 0.96x leverage and CAD 35.0 million in adjusted free cash flow, there are no immediate signs of stress. But the direction of operational margins suggests that the next value stretch lies not in adding revenue, but in making the platform cost less per dollar sold.
The financial verdict is simple and useful for any SME: if gross margins rise and EBITDA falls, the commercial strategy isn’t failing; the cost structure for operating growth is failing. And in the long run, the only growth that maintains control is the one paid by customer cash, not the one depending on acquiring the next quarter.
